Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AZD5363 (capivasertib) in advanced solid malignancies
jRCT2080222792Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in Non-hematologic malignancy, breast cancer, ovarian cancer and 2 more, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD5363, Pharmacokinetics of AZD5363 and 1 more. Started Mar 2015; status: completed.
02
Drugs
capivasertib
03
Conditions
Non-hematologic malignancybreast cancerovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2080222792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222792.